{"id":"W2017088119","doi":"10.1111/cen.12431","title":"Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase <scp>III</scp> study","year":2014,"lang":"en","type":"article","venue":"Clinical Endocrinology","topic":"Pituitary Gland Disorders and Treatments","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Viropharma; Massachusetts General Hospital; Novartis Pharmaceuticals Corporation; Novartis; Pfizer","keywords":"Pasireotide; Medicine; Cushing's disease; Internal medicine; Adverse effect; Randomization; Blood pressure; Gastroenterology; Octreotide; Somatostatin; Disease; Endocrinology; Acromegaly; Clinical trial; Hormone; Growth hormone","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00181554,0.0007477282,0.001525916,0.0001762149,0.0002749279,0.0005698283,0.0004086595,0.0007259556,0.001679231],"category_scores_gemma":[0.0009487536,0.0002568423,0.001387052,0.0002094187,0.0004616653,0.0003888076,0.0001542208,0.001392964,0.0002682293],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003717038,"about_ca_system_score_gemma":0.0006859609,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000624259,"about_ca_topic_score_gemma":0.001109729,"domain_scores_codex":[0.9995956,0.0002234965,0.00003655536,0.00004382684,0.00004388334,0.00005669424],"domain_scores_gemma":[0.9991586,0.0002466906,0.0001927801,0.00007617902,0.00007709317,0.0002486102],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7325112,0.03409803,0.007202126,0.001371416,0.002872108,0.0002342864,0.0002510504,0.000863853,0.08082534,0.0001175683,0.002022795,0.1376303],"study_design_scores_gemma":[0.4992627,0.4582169,0.03383898,0.000072922,0.001122742,0.0003053516,0.00005153074,0.000585351,0.004699491,0.00007366901,0.001736454,0.00003395586],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947525,0.002992891,0.000367667,0.0001795297,0.00005849096,0.0006172332,0.000323373,0.00004047681,0.0006678085],"genre_scores_gemma":[0.99296,0.002300633,0.001455305,0.0006216745,0.0001448083,0.0005976396,0.001140052,0.00002168401,0.0007581968],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00181554,"threshold_uncertainty_score":0.009601593,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03250574179261949,"score_gpt":0.3471564826596509,"score_spread":0.3146507408670314,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}